Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Moderna chief executive officer Stéphane Bancel steps down as chief commercial officer, with president Stephen Hoge assuming ...

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

Both Moderna and Pfizer-BioNTech manufacture the COVID vaccine in lower doses ... A Kaiser Family Foundation survey from 2022 ...

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech ... during the coming 2022/23 flu season in the northern hemisphere.

In the US, Pfizer and BioNTech filed a lawsuit against CureVac in July 2022, seeking confirmation that Comirnaty does not infringe three CureVac patents, and the latter has since filed a ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Today in History for Nov. 9 ...

A new large study of children in California shows that unvaccinated kids are at a much higher risk of developing multisystem ...

Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX), citing the company’s BNT327, an immuno-oncology asset in clinical ...